Renal Cancer

SPARC is a key mediator of TGF-β-induced renal cancer metastasis.

Aberrant expression of transforming growth factor-β1 (TGF-β1) is associated with renal cell carcinoma (RCC) progression by inducing cancer metastasis. However, the downstream effector(s) in TGF-β signaling pathway is not fully characterized.

Contribution and Expression of Organic Cation Transporters and Aquaporin Water Channels in Renal Cancer.

The body homeostasis is maintained mainly by the function of the kidneys, which regulate salt and water balance and excretion of metabolism waste products and xenobiotics. This important renal function is determined by the action of many transport systems, which are specifically expressed in the different parts of the nephron, the functional unit of the kidneys.

MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.

Biphasic squamoid alveolar papillary renal cell carcinoma (BSA-PRCC) is a recently studied lesion considered a morphologic variant of papillary renal cell carcinoma (RCC), more closely related to type 1.

Small Renal Masses in Latin-American Population: Characteristics and Prognostic Factors for Survival, Recurrence and Metastasis – a Multi-Institutional Study from LARCG Database - Beyond the Abstract 

Renal Cell Carcinoma (RCC) in Latin America has been ranked by age-standardized incidence since the 6th (Chile) to the 20th (El Salvador) position in males, and since the 11th (Chile) to above the 20th (Bolivia and El Salvador) position in females.1 Worldwide estimated incidence and mortality of kidney cancer according to GLOBOCAN in 2018 surpassed more than 400,000 cases, and more than 170,000 deaths, respectively.2 Despite that, official government data in Latin America are scarce. Particularly in Brazil, RCC information is not even stated on the website and annual reports of the Brazilian National Cancer Institute until this date.3

Identification of small molecule drugs and development of a novel autophagy-related prognostic signature for kidney renal clear cell carcinoma.

Abnormal autophagic levels have been implicated in the pathogenesis of multiple cancers, however, its role in tumors is complex and has not yet been explored clearly. Hence, we aimed to explore the prognostic values of autophagy-related genes (ARGs) for kidney renal clear cell carcinoma (KIRC).

Patterns of initial metastatic recurrence after surgery for high-risk non-metastatic renal cell carcinoma.

To evaluate postoperative recurrence patterns for high-risk non-metastatic renal cell carcinoma (RCC) and to identify prognostic factors associated with site-specific metastatic recurrence using a multi-institutional contemporary cohort.

Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.

Management of metastatic renal cell cancer (mRCC) has undergone a paradigm shift with immune-checkpoint inhibitors (ICI) in the first-line setting. However, direct comparative data are inadequate to inform treatment decisions.

Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China - Beyond the Abstract

As an aggressive tumor, adult Xp11.2 translocation renal cell carcinoma (RCC) tends to occur in local invasion and lymphatic metastasis even at an early stage, which makes it differ from conventional RCC subtypes, such as clear cell RCC, papillary RCC, and chromophobe RCC. Currently, nephron-sparing surgery (NSS) is more popular than radical nephrectomy (RN) in treating kidney tumors at T1a and selective T1b stage. Although NSS could resect primary kidney tumors completely as RN in most cases, the risk of surgical margin positivity, renal sinus invasion, and vascular invasion gives NSS more potency for recurrence. However, those risk factors are also ignored or undetected by radiological examination before the operation.

Triggers for delayed intervention in patients with small renal masses undergoing active surveillance: a systematic review.

Patients with small renal masses (SRM) can be exposed to overdiagnosis and overtreatment. As such, active surveillance (AS) is recommended by all Guidelines for selected patients. However, it remains underutilized.

Prospective performance of clear cell likelihood scores (ccLS) in renal masses evaluated with multiparametric magnetic resonance imaging.

Solid renal masses have unknown malignant potential with commonly utilized imaging. Biopsy can offer a diagnosis of cancer but has a high non-diagnostic rate and complications. Reported use of multiparametric magnetic resonance imaging (mpMRI) to diagnose aggressive histology (i.

Repeat ablative therapy in hereditary or multifocal renal cancer: Functional and oncological outcomes.

To report managing renal tumors in patients at greater risk of repeated interventions (genetic predisposition, multifocal tumors) with thermoablative treatments (AT). A known significant challenge in these patients is the balance between nephron preservation and oncologic outcome.

LncRNA MEG3 mediates renal cell cancer progression by regulating ST3Gal1 transcription and EGFR sialylation.

Long noncoding RNAs (lncRNAs) have emerged as important regulators of cancer progression. Abnormal sialylation leads to renal cell cancer (RCC) malignancy. However, the mechanism of lncRNA maternally expressed gene 3 (MEG3) mediates RCC progression by regulating ST3Gal1 transcription and EGFR sialylation is still unrevealed.

Fumarate hydratase as a therapeutic target in renal cancer.

Renal cell carcinoma (RCC) is a heterogeneous group of cancers that can occur sporadically or as a manifestation of various inherited syndromes. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is one such inherited syndrome that predisposes patients to HLRCC-associated RCC.

Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma.

Tumour associated trypsin inhibitor (TATI) is a peptide that is a marker for several tumours. TATI may also behave as an acute phase reactant in severe inflammatory disease. Overexpression of TATI predicts an unfavourable outcome for many cancers.

The immunology of renal cell carcinoma.

Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises several subtypes with unique characteristics. The most common subtype (~70% of cases) is clear-cell RCC. RCC is considered to be an immunogenic tumour but is known to mediate immune dysfunction in large part by eliciting the infiltration of immune-inhibitory cells, such as regulatory T cells and myeloid-derived suppressor cells, into the tumour microenvironment.

High-Dimensional Cytometry (ExCYT) and Mass Spectrometry of myeloid infiltrate in clinically localized clear cell Renal Cell Carcinoma identifies novel potential myeloid targets for immunotherapy.

Renal Cell Carcinoma (RCC) is one of the most commonly diagnosed cancers worldwide with research efforts dramatically improving understanding of the biology of the disease.  To investigate the role of the immune system in treatment-naïve clear cell Renal Cell Carcinoma (ccRCC), we interrogated the immune infiltrate in patient-matched ccRCC tumor samples, benign normal adjacent tissue (NAT) and peripheral blood mononuclear cells (PBMCs isolated from whole blood, focusing our attention on the myeloid cell infiltrate.

In vitro evidence of NLRP3 inflammasome regulation by histone demethylase LSD2 in renal cancer: a pilot study.

NLRP3 pathway plays a vital role in the pathogenesis of different human cancers but still the regulation of NLRP3 pathway largely unknown. Therefore, we examined the levels of NLRP3 and its downstream components (caspase-1 and IL-1β) and its relationship with histone modifiers in renal cancer pathogenesis.

Usefulness of multidetector computed tomography to differentiate between renal cell carcinoma and oncocytoma. a model validation.

The purpose of this study is to validate a multivariable predictive model previously developed to differentiate between renal cell carcinoma (RCC) and oncocytoma using computed tomography (CT) parameters.

Development and Validation of a Deep-Learning Model to Assist with Renal Cell Carcinoma Histopathologic Interpretation.

To develop and test the ability of a convolutional neural network (CNN) to accurately identify the presence of renal cell carcinoma (RCC) on histopathology specimens, as well as differentiate RCC histologic subtype and grade.

Bilateral ovarian metastasis of clear-cell renal cell carcinoma: A case report.

Renal cell carcinoma (RCC) accounts for 2-3% of all adult malignancies. Clear-cell type RCC is the most common type, accounting for approximately 75% of all renal cancer cases. The most common sites of metastasis include the lung, bone, and liver.